120 related articles for article (PubMed ID: 29684633)
1. Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial.
Magnan S; Tota JE; El-Zein M; Burchell AN; Schiller JT; Ferenczy A; Tellier PP; Coutlée F; Franco EL;
Clin Microbiol Infect; 2019 Feb; 25(2):210-216. PubMed ID: 29684633
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women (CATCH study): an exploratory phase IIB randomised, placebo-controlled trial.
Laurie C; El-Zein M; Botting-Provost S; Tota JE; Tellier PP; Coutlée F; Burchell AN; Franco EL
EClinicalMedicine; 2023 Jun; 60():102038. PubMed ID: 37396806
[TBL] [Abstract][Full Text] [Related]
3. Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial.
Laurie C; Tota JE; El-Zein M; Tellier PP; Coutlée F; Burchell AN; Franco EL
Contemp Clin Trials; 2021 Nov; 110():106560. PubMed ID: 34487919
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial.
Laurie C; El-Zein M; Tota JE; Khosrow-Khavar F; Tellier PP; Coutlée F; de Pokomandy A; Franco EL;
Sex Transm Infect; 2022 Jun; 98(4):239-246. PubMed ID: 34140405
[TBL] [Abstract][Full Text] [Related]
5. Impact of a carrageenan gel on viral load of genital human papillomavirus infections in sexually active women: Findings from the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) trial.
Laurie C; El-Zein M; Tota JE; Tellier PP; Coutlée F; Burchell AN; Franco EL
J Med Virol; 2024 Apr; 96(4):e29604. PubMed ID: 38606779
[TBL] [Abstract][Full Text] [Related]
6. Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV): design and methods for a randomised controlled trial.
Laurie C; El-Zein M; Tota J; Tellier PP; Coutlée F; Franco EL; de Pokomandy A;
BMJ Open; 2020 Mar; 10(3):e035113. PubMed ID: 32205376
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a Carrageenan Gel in Increasing Clearance of Anal Human Papillomavirus Infections in Men: Interim Analysis of a Double-Blind, Randomized Controlled Trial.
Laurie C; El-Zein M; Tota J; Khosrow-Khavar F; Tellier PP; Coutlée F; de Pokomandy A; Franco EL;
J Infect Dis; 2023 Feb; 227(3):402-406. PubMed ID: 35090175
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection.
Marais D; Gawarecki D; Allan B; Ahmed K; Altini L; Cassim N; Gopolang F; Hoffman M; Ramjee G; Williamson AL
Antivir Ther; 2011; 16(8):1219-26. PubMed ID: 22155903
[TBL] [Abstract][Full Text] [Related]
9. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
Insinga RP; Dasbach EJ; Elbasha EH; Liaw KL; Barr E
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
[TBL] [Abstract][Full Text] [Related]
10. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
11. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.
Insinga RP; Perez G; Wheeler CM; Koutsky LA; Garland SM; Leodolter S; Joura EA; Ferris DG; Steben M; Brown DR; Elbasha EH; Paavonen J; Haupt RM;
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1585-94. PubMed ID: 20530494
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of 5-fluorouracil for the treatment of cervicovaginal human papillomavirus.
Holmes MM; Weaver SH; Vermillion ST
Infect Dis Obstet Gynecol; 1999; 7(4):186-9. PubMed ID: 10449266
[TBL] [Abstract][Full Text] [Related]
13. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results.
Perino A; Consiglio P; Maranto M; De Franciscis P; Marci R; Restivo V; Manzone M; Capra G; Cucinella G; Calagna G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6744-6752. PubMed ID: 31378918
[TBL] [Abstract][Full Text] [Related]
14. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
Teleshova N; Keller MJ; Fernández Romero JA; Friedland BA; Creasy GW; Plagianos MG; Ray L; Barnable P; Kizima L; Rodriguez A; Cornejal N; Melo C; Cruz Rodriguez G; Mukhopadhyay S; Calenda G; Sinkar SU; Bonnaire T; Wesenberg A; Zhang S; Kleinbeck K; Palmer K; Alami M; O'Keefe BR; Gillevet P; Hur H; Liang Y; Santone G; Fichorova RN; Kalir T; Zydowsky TM
PLoS One; 2022; 17(1):e0261775. PubMed ID: 35051209
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.
Qiao YL; Wu T; Li RC; Hu YM; Wei LH; Li CG; Chen W; Huang SJ; Zhao FH; Li MQ; Pan QJ; Zhang X; Li Q; Hong Y; Zhao C; Zhang WH; Li YP; Chu K; Li M; Jiang YF; Li J; Zhao H; Lin ZJ; Cui XL; Liu WY; Li CH; Guo DP; Ke LD; Wu X; Tang J; Gao GQ; Li BY; Zhao B; Zheng FX; Dai CH; Guo M; Zhao J; Su YY; Wang JZ; Zhu FC; Li SW; Pan HR; Li YM; Zhang J; Xia NS
J Natl Cancer Inst; 2020 Feb; 112(2):145-153. PubMed ID: 31086947
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
[TBL] [Abstract][Full Text] [Related]
18. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial.
Ramanakumar AV; Naud P; Roteli-Martins CM; de Carvalho NS; de Borba PC; Teixeira JC; Blatter M; Moscicki AB; Harper DM; Romanowski B; Tyring SK; Ramjattan B; Schuind A; Dubin G; Franco EL;
BMJ Open; 2016 Aug; 6(8):e011371. PubMed ID: 27566633
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial.
Konno R; Tamura S; Dobbelaere K; Yoshikawa H
Int J Gynecol Cancer; 2010 Jul; 20(5):847-55. PubMed ID: 20606533
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
